**Conference Day 1: Wednesday, November 4th 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Registration, Breakfast &amp; Networking</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Chair’s Opening Remarks &amp; Setting the Scene</td>
<td>Kipp Weiskopf, Whitehead Fellow, Whitehead Institute</td>
</tr>
<tr>
<td></td>
<td>- A look at the day ahead - what will be the key takeaways we should achieve by the end of this summit?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- How far have we come in the CD47</td>
<td>SIRP α space since last April?</td>
</tr>
<tr>
<td>9:10</td>
<td>Keynote Presentation: **Fundamental Biology of the CD47</td>
<td>SIRP α Checkpoint**</td>
</tr>
<tr>
<td>9:35</td>
<td>Presentation: **A Novel MOA-reflective Bioassay for Quantifying Potency of Therapeutics Targeting the SIRP α</td>
<td>Jane Lamerdin, Director, R&amp;D, Eurofins DiscoverX</td>
</tr>
<tr>
<td></td>
<td>CD47 Signaling Axis**</td>
<td></td>
</tr>
</tbody>
</table>
10:00  Panel Discussion and Open Q&A: What Impact is our Current Level of Understanding of the CD47|SIRP α Checkpoint Having on the Industry?

- What knowledge do we need to further the development of CD47|SIRP α targeted therapies?
- What are the specific hurdles within research that prevents information about the CD47|SIRP α being discovered?
- Do we understand sufficiently which immune functions are controlled by CD47-SIRP α and how?
- As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

- Dan Pereira, CSO, Arch Oncology
- Michal Caspi Tal, Instructor & Team Lead, Stanford University
- Anthony Schwartz, CEO, Morphix
- Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

10:40  Morning Refreshments & Networking

11:20  Presentation: What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics’ Approach

Nicolas Poirier, CSO, OSE Immunotherapeutics

11:45  Presentation: How Do Macrophages Work In Relation To CD47|SIRP α?

- We learn more about the fundamental biology behind macrophages and how they interact with CD47.
- Why Macrophages rather than dendritic/myeloid cells?
- What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

- Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

12:10  Panel Discussion and Open Q&A: What Does “Eat Me” Mechanistically Mean for Macrophages In Relation To CD47|SIRP α?

- How do we activate and how do we increase macrophage activity?
- What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
- Can CD47/SIRPa blockade single handedly influence what macrophages do with the tumor antigens after they are ‘eaten’?
- What other signals/pathways in macrophages need to be engaged?
- How do we measure/confirm macrophage phagocytosis in a clinical trial setting?

- Siddhartha Mitra, Assistant Professor, University of Colorado
- Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim
- Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute
- Yoji Murata, Associate Professor, Dean of the Graduate School of Medicine, Kobe University

12:50

Lunch & Networking

Combinations in Action

1:50 Presentation: QPCTL - A Druggable Modifier of the CD47/SIRP Therapeutic Axis

Bastiaan Evers, Senior Director of Drug Discovery, Scenic Biotech

2:15 Panel Discussion and Open Q&A: Chemotherapy, T-cell Immunotherapy and Radiotherapy - Where do these Fit in Combination with CD47|SIRP α?

- What do we know so far about combining these targets with CD47|SIRP α both preclinically and clinically?
- How effectively does radiotherapy work alongside CD47|SIRP α?
- What are the risks of combining these immuno-oncology targets?
- What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|Sirpa compounds, does one route work better than the other?
- How predictive/how useful are preclinical models in this space?

- Siddhartha Mitra, Assistant Professor, University of Colorado
- André Veillette, Professor, Department of Medicine, University of Montreal
- Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

CD47|SIRP α in the Clinic

2:50 Presentation: Tackling Solid Cancers using a Bispecific Antibody Approach - Light Chain Bioscience

- A look at the advantages of targeting CD47 with a bispecific antibody approach.
- We hear about Mesothelin as a target for solid cancers.
- An insight into preclinical data for the CD47 x Mesothelin bispecific antibody.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15</td>
<td>Afternoon Refreshments &amp; Networking</td>
</tr>
</tbody>
</table>
| 4:00   | Presentation: **ALX148: Designed For Safety To Maximize Efficacy.**  
  - Design of ALX148 and mechanistic insights into its safety/efficacy profile  
  - Overview of clinical results from the ALX148 program |
|        | **Jaume Pons**, President & CEO, **ALX Oncology** |
| 4:25   | Presentation: **TJC4 – A Differentiated CD47 Antibody in Clinical Development**  
  - An insight into how I-Mab Biopharma discovered an antibody with differentiated properties to reduce RBC binding.  
  - We learn about I-Mab Biopharma’s attempt to understand the mechanisms underlying these differentiated properties. |
|        | **Claire Xu**, Head of US Site, **I-Mab Biopharma** |
| 4:50   | Panel Discussion and Open Q&A: **What are the Predictive Biomarkers Arising when Targeting CD47|SIRP α Pathways?**  
  - What are the best biomarker strategies to validate how clinical trials are going?  
  - SIRP α/CD47 tumoral expression: is there any correlation with clinical efficacy?  
  - Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?  
  - What other biomarkers should be considered in regards to CD47|SIRP α drugs?  
  - What biomarkers are biotech companies using to track macrophages in clinic? |
|        | Moderated by: **Nicolas Poirier**, CSO, **OSE Immunotherapeutics**  
  - **Claire Xu**, Head of US Site, I-Mab Biopharma  
  - **André Veillette**, Professor, Department of Medicine, University of Montreal  
  - **Spencer Liang**, Senior Director, Head of Immuno-Oncology, Alector  
  - **Limin Shang**, Pharmacology Director, LightChain Bioscience |
| 5:30   | Close of Day 1 |
Conference Day 2: Thursday, November 5th 2020

9:00  Chair’s Opening Remarks & Setting the Scene

- What have we learnt so far at CD47|SIRP α 2020?
- What can we expect from today?

Siddhartha Mitra, Assistant Professor, University of Colorado

9:10  Presentation: An Insight into Trillium Therapeutics’ Progress and What’s To Come.

Yaping Shou, Chief Medical Officer, Trillium Therapeutics


Michal Caspi Tal, Instructor & Team Lead, Stanford University

Building Clinical Best Practice

10:00  Panel Discussion and Open Q&A: How Can we Manage Toxicity and Improve Clinical Practice?

- What toxicities have been identified during preclinical & clinical trials?
- Are there specific causes for toxicity and how can we negate these?
- Are pre-clinical non-human samples posing problems for future clinical trials?
- The RACE For Children Act comes into effect in August 2020, how will this affect clinical trials?
- How else can we build best practices in clinic?

- Tabitha Cooney, Physician, Neuro-Oncology, Dana Farber Cancer Institute
- Michael Dougan, Assistant Professor, Medicine, Harvard Medical School
- Daniel Masylar, VP of Clinical Development for Oncology, Alector
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Presenter</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>Morning Refreshments &amp; Networking</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Additional Pathways - What Else Is In The Pipeline?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity.</td>
<td>Taylor Schreiber, CEO, Shattuck Labs</td>
<td></td>
</tr>
</tbody>
</table>
| 11:55 | Presentation: AO-176, A Highly Differentiated Clinical Stage Anti-CD47 Antibody. | Dan Pereira, CSO, Arch Oncology | - We learn how Arch Oncology is working to bridge innate and adaptive anti-tumor immunity through development of AO-176.  
- An insight into the clinical trials for AO-176 and what’s to come.  

|       | Presentation: An Insight Into Alector’s Novel Approach to Drive Anti-Tumor Immunity. | Andrew Picentic, Staff Scientist & Program Lead, Alector |         |
| 12:45 | Lunch & Networking                                                    |                                                        |         |
|       | What’s On The Horizon?                                                |                                                        |         |
| 2:15  | Panel Discussion and Open Q&A: Reflection and Progression - Where are We and What’s Next for CD47/SIRP α? |                                                        |         |
|       | - What challenges have we faced and how can we overcome these?        |                                                        |         |
|       | - Where do we expect to see the most growth in the next year?         |                                                        |         |
|       | - Should enhancing mediated-macrophage phagocytosis be a focus going forward? |                                                        |         |
|       | - How is the future work on emerging "don’t eat me" signals going to benefit from our work with CD47/SIRP α? |                                                        |         |
- What have been our biggest takeaways from the CD47/SIRPa 2020 Summit

  - **Timothy Zheng**, Executive Director, Immune Modulation, Boehringer Ingelheim
  - **Taylor Schreiber**, CEO, Shattuck Labs
  - **Bastiaan Evers**, Senior Director of Drug Discovery, Scenic Biotech

2:55 Chairs Closing Remarks

- What have been the key learnings from CD47|SIRPa 2020?

**Siddhartha Mitra**, Assistant Professor, University of Colorado

3:00 Close of CD47|SIRPa 2020